Literature DB >> 18411060

Measurement of GABAA receptor binding in vivo with [11C]flumazenil: a test-retest study in healthy subjects.

Elina Salmi1, Sargo Aalto, Jussi Hirvonen, Jaakko W Långsjö, Anu T Maksimow, Vesa Oikonen, Liisa Metsähonkala, Jussi Virkkala, Kjell Någren, Harry Scheinin.   

Abstract

[(11)C]Flumazenil is widely used in positron emission tomography (PET) studies to measure GABA(A) receptors in vivo in humans. Although several different methods have been applied for the quantification of [(11)C]flumazenil binding, the reproducibility of these methods has not been previously examined. The reproducibility of a single bolus [(11)C]flumazenil measurements was studied by scanning eight healthy volunteers twice during the same day. Grey matter regions were analyzed using both regions-of-interest (ROI) and voxel-based analysis methods. Compartmental kinetic modelling using both arterial and reference region input function were applied to derive the total tissue distribution volume (V(T)) and the binding potential (BP) (BP(P) and BP(ND)) of [(11)C]flumazenil. To measure the reproducibility and reliability of each [(11)C]flumazenil binding parameter, absolute variability values (VAR) and intraclass correlation coefficients (ICC) were calculated. Tissue radioactivity concentration over time was best modelled with a 2-tissue compartmental model. V(T) showed with all methods good to excellent reproducibility and reliability with low VARs (mean of all brain regions) (5.57%-6.26%) and high ICCs (mean of all brain regions) (0.83-0.88) when using conventional ROI analysis. Also voxel-based analysis methods yielded excellent reproducibility (VAR 5.75% and ICC 0.81). In contrast, the BP estimates using pons as the reference tissue yielded higher VARs (8.08%-9.08%) and lower ICCs (0.35-0.80). In conclusion, the reproducibility of [(11)C]flumazenil measurements is considerably better with outcome measures based on arterial input function than those using pons as the reference tissue. The voxel-based analysis methods are proper alternative as the reliability is preserved and analysis automated.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18411060     DOI: 10.1016/j.neuroimage.2008.02.035

Source DB:  PubMed          Journal:  Neuroimage        ISSN: 1053-8119            Impact factor:   6.556


  20 in total

1.  Towards PET imaging of intact pancreatic beta cell mass: a transgenic strategy.

Authors:  Rebecca McGirr; Shirley Hu; Siu-Pok Yee; Michael S Kovacs; Ting-Yim Lee; Savita Dhanvantari
Journal:  Mol Imaging Biol       Date:  2011-10       Impact factor: 3.488

2.  Positron emission tomography imaging of dopamine D₂/₃ receptors in the human cortex with [¹¹C]FLB 457: reproducibility studies.

Authors:  Rajesh Narendran; N Scott Mason; Maureen A May; Chi-Min Chen; Steve Kendro; Khanum Ridler; Eugenii A Rabiner; Marc Laruelle; Chester A Mathis; W Gordon Frankle
Journal:  Synapse       Date:  2011-01       Impact factor: 2.562

3.  Reproducibility of automated simplified voxel-based analysis of PET amyloid ligand [11C]PIB uptake using 30-min scanning data.

Authors:  Sargo Aalto; Noora M Scheinin; Nina M Kemppainen; Kjell Någren; Marita Kailajärvi; Mika Leinonen; Mika Scheinin; Juha O Rinne
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-06-04       Impact factor: 9.236

4.  GABAA receptor deficits predict recovery in patients with disorders of consciousness: A preliminary multimodal [(11) C]Flumazenil PET and fMRI study.

Authors:  Pengmin Qin; Xuehai Wu; Niall W Duncan; Weiqi Bao; Weijun Tang; Zhengwei Zhang; Jin Hu; Yi Jin; Xing Wu; Liang Gao; Lu Lu; Yihui Guan; Timothy Lane; Zirui Huang; Yelena G Bodien; Joseph T Giacino; Ying Mao; Georg Northoff
Journal:  Hum Brain Mapp       Date:  2015-07-03       Impact factor: 5.038

5.  External awareness and GABA--a multimodal imaging study combining fMRI and [18F]flumazenil-PET.

Authors:  Christine Wiebking; Niall W Duncan; Pengmin Qin; Dave J Hayes; Oliver Lyttelton; Paul Gravel; Jeroen Verhaeghe; Alexey P Kostikov; Ralf Schirrmacher; Andrew J Reader; Malek Bajbouj; Georg Northoff
Journal:  Hum Brain Mapp       Date:  2012-09-21       Impact factor: 5.038

6.  Human biodistribution and dosimetry of the PET radioligand [¹¹C]flumazenil (FMZ).

Authors:  Charles M Laymon; Rajesh Narendran; Neale S Mason; Jonathan P Carney; Brian J Lopresti; Chester A Mathis; James M Mountz; Donald Sashin; W Gordan Frankle
Journal:  Mol Imaging Biol       Date:  2012-02       Impact factor: 3.488

7.  GABAA receptors predict aversion-related brain responses: an fMRI-PET investigation in healthy humans.

Authors:  Dave J Hayes; Niall W Duncan; Christine Wiebking; Karin Pietruska; Pengmin Qin; Stefan Lang; Jean Gagnon; Paul Gravel Bing; Jeroen Verhaeghe; Alexey P Kostikov; Ralf Schirrmacher; Andrew J Reader; Julien Doyon; Pierre Rainville; Georg Northoff
Journal:  Neuropsychopharmacology       Date:  2013-02-06       Impact factor: 7.853

8.  Reduced binding potential of GABA-A/benzodiazepine receptors in individuals at ultra-high risk for psychosis: an [18F]-fluoroflumazenil positron emission tomography study.

Authors:  Jee In Kang; Hae-Jeong Park; Se Joo Kim; Kyung Ran Kim; Su Young Lee; Eun Lee; Suk Kyoon An; Jun Soo Kwon; Jong Doo Lee
Journal:  Schizophr Bull       Date:  2013-04-15       Impact factor: 9.306

9.  Quantification of [11C]Ro15-4513 GABAAα5 specific binding and regional selectivity in humans.

Authors:  Jim Fm Myers; Robert A Comley; Roger N Gunn
Journal:  J Cereb Blood Flow Metab       Date:  2016-01-01       Impact factor: 6.200

10.  In vivo validation of reconstruction-based resolution recovery for human brain studies.

Authors:  Jurgen E M Mourik; Mark Lubberink; Floris H P van Velden; Reina W Kloet; Bart N M van Berckel; Adriaan A Lammertsma; Ronald Boellaard
Journal:  J Cereb Blood Flow Metab       Date:  2009-10-21       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.